دورية أكاديمية
Transcriptional diversity of long-term glioblastoma survivors
| العنوان: | Transcriptional diversity of long-term glioblastoma survivors |
|---|---|
| المؤلفون: | Gerber, N. K., Goenka, A., Turcan, S., Reyngold, M., Makarov, V., Kannan, K., Beal, K., Brennan, C. W., Huse, J. T., Chan, T. A., +3 additional authors |
| المصدر: | Journal Articles |
| بيانات النشر: | Donald and Barbara Zucker School of Medicine Academic Works |
| سنة النشر: | 2014 |
| المجموعة: | Hofstra Northwell Academic Works (Hofstra Northwell School of Medicine) |
| مصطلحات موضوعية: | Tcga, gene expression, glioblastoma, prognostic genes, Neoplasms |
| الوصف: | BACKGROUND: Glioblastoma (GBM) is a highly aggressive type of glioma with poor prognosis. However, a small number of patients live much longer than the median survival. A better understanding of these long-term survivors (LTSs) may provide important insight into the biology of GBM. METHODS: We identified 7 patients with GBM, treated at Memorial Sloan-Kettering Cancer Center (MSKCC), with survival >48 months. We characterized the transcriptome of each patient and determined rates of MGMT promoter methylation and IDH1 and IDH2 mutational status. We identified LTSs in 2 independent cohorts (The Cancer Genome Atlas [TCGA] and NCI Repository for Molecular Brain Neoplasia Data [REMBRANDT]) and analyzed the transcriptomal characteristics of these LTSs. RESULTS: The median overall survival of our cohort was 62.5 months. LTSs were distributed between the proneural (n = 2), neural (n = 2), classical (n = 2), and mesenchymal (n = 1) subtypes. Similarly, LTS in the TCGA and REMBRANDT cohorts demonstrated diverse transcriptomal subclassification identities. The majority of the MSKCC LTSs (71%) were found to have methylation of the MGMT promoter. None of the patients had an IDH1 or IDH2 mutation, and IDH mutation occurred in a minority of the TCGA LTSs as well. A set of 60 genes was found to be differentially expressed in the MSKCC and TCGA LTSs. CONCLUSIONS: While IDH mutant proneural tumors impart a better prognosis in the short-term, survival beyond 4 years does not require IDH mutation and is not dictated by a single transcriptional subclass. In contrast, MGMT methylation continues to have strong prognostic value for survival beyond 4 years. These findings have substantial impact for understanding GBM biology and progression. |
| نوع الوثيقة: | text |
| وصف الملف: | application/pdf |
| اللغة: | unknown |
| العلاقة: | https://academicworks.medicine.hofstra.edu/publications/102Test; https://academicworks.medicine.hofstra.edu/context/publications/article/1103/viewcontent/Neuro_Oncology2014v16p1186.pdfTest |
| DOI: | 10.1093/neuonc/nou043 |
| الإتاحة: | https://doi.org/10.1093/neuonc/nou043Test https://academicworks.medicine.hofstra.edu/publications/102Test https://academicworks.medicine.hofstra.edu/context/publications/article/1103/viewcontent/Neuro_Oncology2014v16p1186.pdfTest |
| رقم الانضمام: | edsbas.DB955FEB |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/neuonc/nou043 |
|---|